Skip to main content
. Author manuscript; available in PMC: 2022 Jul 7.
Published in final edited form as: J Thorac Oncol. 2021 Apr 8;16(7):1149–1165. doi: 10.1016/j.jtho.2021.03.013

Figure 3. Identification and characterization of activated signaling pathways in NRG1 fusion-driven lung cancers.

Figure 3.

A. Principal component analysis demonstrated distinctive grouping of NRG1-rearranged lung tumor samples. B. GSEA analysis was performed to compare NRG1-rearragned lung cancer samples and healthy lung tissue gene expression (TCGA LUAD and LUSC datasets). The top 40 significantly enriched pathways from MSigDB (HALLMARK and Oncogenic signatures, combined) are demonstrated. C. Enrichment plot depicting significantly enriched AKT-MTOR related signatures. While corresponding upregulation were positively enriched, downregulation signatures demonstrated negative scores, consistent with a hypothesis of AKT-MTOR-associated transcriptomic changes. D. Whole-cell extracts were prepared from serum-starved cells and subjected to Western blotting analysis. Representative immunoblots are shown. Two independent experiments were conducted.